Evolus outlines 2026 revenue guidance of $327M-$337M while expanding international presence and product portfolio
Source: SeekingAlpha
2026-03-04 02:42:47 ET
More on Evolus
- Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript
- Evolus, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Evolus: A Difficult 2025 Means I'm Downgrading Stock To 'Hold' For 2026
- Evolus GAAP EPS of $0.00 beats by $0.05, revenue of $90.3M beats by $0.72M
- Evolus sees Q4 net revenue between $88.6M and $90.6M
Read the full article on Seeking Alpha
For further details see:
Evolus outlines 2026 revenue guidance of $327M–$337M while expanding international presence and product portfolio
Evolus Inc.
NASDAQ: EOLS
EOLS Trading
2.85% G/L:
$5.37 Last:
398,630 Volume:
$5.54 Open:
EOLS Latest News
EOLS Stock Data
$288,448,039
43,258,131
1.1%
49
N/A
Pharmaceuticals
Healthcare
US
Newport Beach
